Amedeo Smart

Free Medical Literature Service


 

Amedeo

Gastric Cancer

  Free Subscription

Articles published in
Eur J Cancer
    September 2021
  1. HE X, Gu Y, Cao Y, Hu B, et al
    Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
    Eur J Cancer. 2021;157:114-123.
    >> Share

    April 2021
  2. DEGIULI M, Reddavid R, Tomatis M, Ponti A, et al
    D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial.
    Eur J Cancer. 2021;150:10-22.
    >> Share

    December 2020
  3. PARK S, Nam CM, Kim SG, Mun JE, et al
    Comparative efficacy and tolerability of third-line treatments for advanced gastric cancer: A systematic review with Bayesian network meta-analysis.
    Eur J Cancer. 2020;144:49-60.
    >> Share

    November 2020
  4. DIJKSTERHUIS WPM, Verhoeven RHA, Pape M, Slingerland M, et al
    Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
    Eur J Cancer. 2020;139:107-118.
    >> Share

    September 2020
  5. ATHAUDA A, Nankivell M, Langley RE, Alderson D, et al
    Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03).
    Eur J Cancer. 2020;137:45-56.
    >> Share

    August 2020
  6. GIULIANI J, Bonetti A
    Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
    Eur J Cancer. 2020;138:77-79.
    >> Share

  7. BANG YJ, Golan T, Dahan L, Fu S, et al
    Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
    Eur J Cancer. 2020;137:272-284.
    >> Share

    May 2020
  8. NISHIKAWA K, Murotani K, Fujitani K, Inagaki H, et al
    Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TR
    Eur J Cancer. 2020;132:159-167.
    >> Share

  9. VAN DER KAAIJ RT, Koemans WJ, van Putten M, Snaebjornsson P, et al
    A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015.
    Eur J Cancer. 2020;130:23-31.
    >> Share

  10. ZHENG Y, Yang X, Yan C, Feng R, et al
    Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial.
    Eur J Cancer. 2020;130:12-19.
    >> Share

    April 2020
  11. KAWAZOE A, Yamaguchi K, Yasui H, Negoro Y, et al
    Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
    Eur J Cancer. 2020;129:97-106.
    >> Share

    March 2020
  12. SLAGTER AE, Tudela B, van Amelsfoort RM, Sikorska K, et al
    Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial.
    Eur J Cancer. 2020;130:146-154.
    >> Share

    February 2020
  13. LIU X, Cao Y, Li R, Gu Y, et al
    Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.
    Eur J Cancer. 2020;128:27-37.
    >> Share

    January 2020
  14. VAN CUTSEM E, Muro K, Cunningham D, Bodoky G, et al
    Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Eur J Cancer. 2020;127:150-157.
    >> Share

  15. WAGNER AD, Lordick F, Grabsch HI, Terashima M, et al
    Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
    Eur J Cancer. 2020;124:67-76.
    >> Share

    November 2019
  16. THOMAS A, Virdee PS, Eatock M, Lord SR, et al
    Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma.
    Eur J Cancer. 2019;124:131-141.
    >> Share

    June 2019
  17. OBERMANNOVA R, Valik D, Hasenclever D, Zdrazilova-Dubska L, et al
    High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact.
    Eur J Cancer. 2019;116:107-113.
    >> Share

    March 2019
  18. KIM C, Chon HJ, Kim JH, Jung M, et al
    Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
    Eur J Cancer. 2019;112:20-28.
    >> Share

    December 2018
  19. CHAU I, Fuchs CS, Ohtsu A, Barzi A, et al
    Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
    Eur J Cancer. 2018;107:115-123.
    >> Share

    November 2018
  20. SAEKI H, Oki E, Kashiwada T, Arigami T, et al
    Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Eur J Cancer. 2018;105:41-49.
    >> Share

    September 2018
  21. SAHIN U, Schuler M, Richly H, Bauer S, et al
    A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer.
    Eur J Cancer. 2018;100:17-26.
    >> Share

    August 2018
  22. NISHIKAWA K, Tsuburaya A, Yoshikawa T, Kobayashi M, et al
    A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Eur J Cancer. 2018;101:220-228.
    >> Share

    July 2018
  23. MIZRAK KAYA D, Nogueras-Gonzales GM, Harada K, Amlashi FG, et al
    Potentially curable gastric adenocarcinoma treated without surgery.
    Eur J Cancer. 2018;98:23-29.
    >> Share

    April 2018
  24. STAHL M, Maderer A, Lordick F, Mihaljevic AL, et al
    Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (
    Eur J Cancer. 2018;93:119-126.
    >> Share

    March 2018
  25. HEWITT LC, Inam IZ, Saito Y, Yoshikawa T, et al
    Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Eur J Cancer. 2018;94:104-114.
    >> Share

  26. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    Potential impact of molecular classification on tailored lymphadenectomy for gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S8.
    >> Share

  27. CHIAPPA A, Bertani E, Fazio N, Foschi D, et al
    D2-lymphadenectomy and gastric resection in a consecutive series of patients with gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S7.
    >> Share

  28. BENCIVENGA M, Treppiedi E, Verlato G, Mengardo V, et al
    The amount of cells with Signet Ring Cell morphology has a prognostic impact in poorly cohesive gastric carcinoma.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    >> Share

  29. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    K-RAS mutation in gastric cancer and its link with microsatellite instability status.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    >> Share

  30. CARNEIRO F
    Hereditary gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4.
    >> Share

  31. ROVIELLO F
    The role of HIPEC in gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4-S5.
    >> Share

  32. TERASHIMA M
    Perioperative treatment strategies and current studies to improve gastric cancer outcomes in Japan.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    >> Share

  33. LORDICK F
    Response-adapted treatment stratification in oesophago-gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    >> Share

  34. LAURENT-PUIG P
    Oesophago-gastric cancer: One disease or separate entities?: Translating molecular subtyping into clinical practice.
    Eur J Cancer. 2018;92 Suppl 2:S1.
    >> Share

  35. NASR F, El Rassy E, Maalouf G, Azar C, et al
    Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
    Eur J Cancer. 2018;91:171-173.
    >> Share

    February 2018
  36. SPOERL S, Novotny A, Al-Batran SE, Lordick F, et al
    Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
    Eur J Cancer. 2018;90:26-33.
    >> Share

    January 2018
  37. BANDO H, Shimodaira H, Fujitani K, Takashima A, et al
    A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Eur J Cancer. 2018;91:86-91.
    >> Share

    December 2017
  38. WANG H, Li B, Liu Z, Gong J, et al
    HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Eur J Cancer. 2017;88:92-100.
    >> Share

    August 2017
  39. COURTOIS S, Duran RV, Giraud J, Sifre E, et al
    Metformin targets gastric cancer stem cells.
    Eur J Cancer. 2017;84:193-201.
    >> Share

  40. STAHL M, Walz MK, Riera-Knorrenschild J, Stuschke M, et al
    Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
    Eur J Cancer. 2017;81:183-190.
    >> Share

  41. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    >> Share

    July 2017
  42. PARK SR, Kim MJ, Nam BH, Kim CG, et al
    A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
    Eur J Cancer. 2017;83:32-42.
    >> Share

  43. KEMPF E, Tournigand C, Rochigneux P, Aubry R, et al
    Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
    Eur J Cancer. 2017;79:31-40.
    >> Share

  44. PERNOT S, Badoual C, Terme M, Castan F, et al
    Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
    Eur J Cancer. 2017;79:15-22.
    >> Share

    June 2017
  45. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    >> Share

  46. HAJ MOHAMMAD N, Bernards N, van Putten M, Lemmens VEPP, et al
    Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
    Eur J Cancer. 2017;78:28-36.
    >> Share

    May 2017
  47. FARAG S, Somaiah N, Choi H, Heeres B, et al
    Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Eur J Cancer. 2017;76:76-83.
    >> Share

  48. PETRELLI F, Tomasello G, Barni S
    Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Eur J Cancer. 2017;76:8-16.
    >> Share

    April 2017
  49. DESIDERIO J, Chao J, Melstrom L, Warner S, et al
    The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
    Eur J Cancer. 2017;79:1-14.
    >> Share

    February 2017
  50. IENI A, Angelico G, Zeppa P, Tuccari G, et al
    Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER
    Eur J Cancer. 2017;75:190-191.
    >> Share

    December 2016
  51. OH HJ, Lim CH, Yoon BH, Yoon SB, et al
    Fracture after gastrectomy for gastric cancer: A long-term follow-up observational study.
    Eur J Cancer. 2016;72:28-36.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016